INT53487

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 1994
Last Reported 2011
Negated 1
Speculated 1
Reported most in Body
Documents 81
Total Number 82
Disease Relevance 77.71
Pain Relevance 7.94

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (TSC1) embryo development (TSC1) protein complex (TSC1)
cytoplasm (TSC1)
Anatomy Link Frequency
hepatocytes 1
colon 1
brain 1
neuroendocrine cells 1
cleavage 1
TSC1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Chronic pancreatitis 23 99.92 Very High Very High Very High
qutenza 37 99.84 Very High Very High Very High
cINOD 53 99.76 Very High Very High Very High
cytokine 68 99.26 Very High Very High Very High
agonist 109 98.68 Very High Very High Very High
Inflammatory mediators 8 98.68 Very High Very High Very High
Inflammation 256 98.12 Very High Very High Very High
rheumatoid arthritis 83 96.20 Very High Very High Very High
opioid receptor 3 95.88 Very High Very High Very High
Central nervous system 46 95.56 Very High Very High Very High
Disease Link Frequency Relevance Heat
Cancer 4072 100.00 Very High Very High Very High
Microsatellite Instability 57 100.00 Very High Very High Very High
Pancreatitis 43 99.92 Very High Very High Very High
Neuroendocrine Cancer 11 99.92 Very High Very High Very High
Cholesteatoma 120 99.84 Very High Very High Very High
Hyperplasia 81 99.72 Very High Very High Very High
Skin Cancer 187 99.68 Very High Very High Very High
Disease 527 99.64 Very High Very High Very High
Nasopharynx Cancer 212 99.56 Very High Very High Very High
Neuroblastoma 77 99.54 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
TSC1/2 complex inhibits mTOR and is normally expressed in neuroendocrine cells.3 Patients with a defect in the TSC2 gene have tuberous sclerosis and are known to develop islet cell carcinoma.4 Neurofibromatosis is associated with the development of carcinoid tumors of the ampulla of Vater, duodenum, and mediastinum.5,6 The gene responsible for neurofibromatosis 1 (NF1) regulates the activity of TSC2.
Gene_expression (expressed) of TSC1 in neuroendocrine cells associated with hypoglycemia, carcinoid, tuberous sclerosis, neurofibromatosis and watson syndrome
1) Confidence 0.58 Published 2007 Journal Ann Surg Oncol Section Body Doc Link PMC2077912 Disease Relevance 2.66 Pain Relevance 0
TSC1 and TSC2 products, known as hamartin and tuberin, act as a heterodimer; thus the inactivation of either gene impairs the same pathway leading to the same clinical phenotype [49-51].
Gene_expression (products) of TSC1
2) Confidence 0.52 Published 2005 Journal Hered Cancer Clin Pract Section Body Doc Link PMC2837065 Disease Relevance 1.37 Pain Relevance 0
From June, 1998 through December, 2003, 25 patients transplanted for HBV were managed on chronic LAM therapy.
Gene_expression (therapy) of LAM associated with hepatitis b virus infection
3) Confidence 0.52 Published 2006 Journal Ann Clin Microbiol Antimicrob Section Body Doc Link PMC1459192 Disease Relevance 0.30 Pain Relevance 0
Toniutto's study [22] describes one patient who developed de novo HBV graft infection. 3 months after treatment of LAM, LAM resistance developed.
Gene_expression (resistance) of LAM associated with hepatitis b virus infection and infection
4) Confidence 0.52 Published 2006 Journal Ann Clin Microbiol Antimicrob Section Body Doc Link PMC1459192 Disease Relevance 1.11 Pain Relevance 0
Toniutto's study [22] describes one patient who developed de novo HBV graft infection. 3 months after treatment of LAM, LAM resistance developed.
Gene_expression (resistance) of LAM associated with hepatitis b virus infection and infection
5) Confidence 0.52 Published 2006 Journal Ann Clin Microbiol Antimicrob Section Body Doc Link PMC1459192 Disease Relevance 1.11 Pain Relevance 0
LAM is preferred over the use of the Interferons which are contraindicated in patients with advanced cirrhosis. [3-7]
Gene_expression (preferred) of LAM associated with cirrhosis
6) Confidence 0.52 Published 2006 Journal Ann Clin Microbiol Antimicrob Section Body Doc Link PMC1459192 Disease Relevance 0.94 Pain Relevance 0.11
In 2004, Neff et. al. [21] reported the successful use of Tenofovir in patients who developed the Lam resistance following OLT.
Gene_expression (resistance) of Lam
7) Confidence 0.52 Published 2006 Journal Ann Clin Microbiol Antimicrob Section Body Doc Link PMC1459192 Disease Relevance 0.35 Pain Relevance 0
Unlike the use of LAM, no resistance to ADV was identified after 48 weeks of therapy in this population. [71] Many patients came off the transplant list because of reversal of the decompensated state.
Gene_expression (use) of LAM
8) Confidence 0.52 Published 2006 Journal Ann Clin Microbiol Antimicrob Section Body Doc Link PMC1459192 Disease Relevance 0.60 Pain Relevance 0.03
Other mutations can occur at Domain B in conjunction with the YMDD mutations. [52] Liaw showed that the cumulative rates of LAM resistance were 14%, 38%, 49%, 66% and 69%, one, two, three, four, and five years after initial therapy respectively. [53] Other studies have showed similar rates of resistance with resistance rates of 24% and 70% after one and four years of therapy respectively. [50,51,54]
Gene_expression (resistance) of LAM
9) Confidence 0.52 Published 2006 Journal Ann Clin Microbiol Antimicrob Section Body Doc Link PMC1459192 Disease Relevance 0.52 Pain Relevance 0
Gene mutations and abnormal gene expression, particularly of oncogenes and tumor suppressor genes, are often observed in myeloma cells.
Gene_expression (expression) of tumor suppressor associated with cancer
10) Confidence 0.48 Published 2006 Journal Ther Umsch Section Abstract Doc Link 16689452 Disease Relevance 0.61 Pain Relevance 0.11
The TSC genes TSC1 and TSC2 were first identified by positional cloning strategies.
Gene_expression (identified) of TSC
11) Confidence 0.39 Published 2008 Journal Current Genomics Section Body Doc Link PMC2691673 Disease Relevance 0.38 Pain Relevance 0
Although clinical expression of TSC varies greatly, in its classic form, there is 100% penetrance.
Gene_expression (expression) of TSC
12) Confidence 0.39 Published 2008 Journal Current Genomics Section Body Doc Link PMC2691673 Disease Relevance 0.72 Pain Relevance 0
Features of TSC and autosomal dominant PKD have been observed in patients with a TSC2-PKD1 contiguous gene syndrome.
Gene_expression (Features) of TSC associated with syndrome and disease
13) Confidence 0.34 Published 2008 Journal Current Genomics Section Body Doc Link PMC2691673 Disease Relevance 0.65 Pain Relevance 0
It has been reported that TSC expressing the markers Nestin and CD133 in a variety of brain tumors [13].
Gene_expression (expressing) of TSC in brain associated with brain tumor
14) Confidence 0.29 Published 2008 Journal J Exp Clin Cancer Res Section Body Doc Link PMC2633002 Disease Relevance 0.60 Pain Relevance 0
To address this problem, we investigate, in this study, the expression of two TSC markers – Nestin and CD133, which are the most accredited markers for the identification of NSCs and have been used to fundamentally reveal the biological properties of TSCs, on protein level.
Spec (investigate) Gene_expression (expression) of TSC
15) Confidence 0.19 Published 2008 Journal J Exp Clin Cancer Res Section Body Doc Link PMC2633002 Disease Relevance 0.72 Pain Relevance 0.07
TSC was suspected in patients with facial angiofibromas, mental retardation, seizure, or pulmonary lymphangiomyomatosis, and were categorized as definite when positive for TSC1 and TSC2 loss of heterozygosity.


Gene_expression (suspected) of TSC associated with convulsion, intellectual impairment, nasal tumor and lymphangioleiomyomatosis
16) Confidence 0.09 Published 2010 Journal Yonsei Medical Journal Section Body Doc Link PMC2908871 Disease Relevance 1.19 Pain Relevance 0.20
For example, we found an increased expression of the oncogenic miR-21 in B-DIM treated Colo-357 which was unexpected, whereas most of the results displayed decreased expression of oncogenic miRNAs and increased expression of tumor suppressor miRNAs upon treatment with either agent, clearly supporting the role of B-DIM or G2535 as cancer preventing agents.
Gene_expression (expression) of tumor suppressor associated with cancer
17) Confidence 0.08 Published 2008 Journal Current Genomics Section Body Doc Link PMC2674802 Disease Relevance 0.48 Pain Relevance 0
As stated earlier, let-7 functions as a tumor suppressor and is poorly expressed or deleted in human tumors.
Gene_expression (expressed) of tumor suppressor associated with cancer
18) Confidence 0.08 Published 2008 Journal Current Genomics Section Body Doc Link PMC2674802 Disease Relevance 0.70 Pain Relevance 0
Hence, it was concluded that miR-34a plays a very important role in controlling gene expression of the p53 tumor suppressor network components.
Gene_expression (expression) of tumor suppressor associated with cancer
19) Confidence 0.08 Published 2008 Journal Current Genomics Section Body Doc Link PMC2674802 Disease Relevance 0.83 Pain Relevance 0
Various regulatory factors control the expression of genes such as tumor suppressor genes and oncogenes, allowing for the timely and coordinated execution of these processes.
Gene_expression (expression) of tumor suppressor associated with cancer
20) Confidence 0.08 Published 2008 Journal Current Genomics Section Body Doc Link PMC2674802 Disease Relevance 1.27 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox